The Claim
In adults with overweight or obesity, a weekly dose of 2.4 mg of pemvidutide results in greater weight loss compared to weekly doses of 1.2 mg and 1.8 mg, indicating a dose-response relationship for weight loss efficacy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with overweight or obesity, taking 2.4 mg of pemvidutide once a week leads to more weight loss than taking 1.2 mg or 1.8 mg weekly, suggesting that higher doses produce greater effects.
See the scientific wording
In adults with overweight or obesity, the 2.4 mg weekly dose of pemvidutide produces greater weight loss than lower doses (1.2 mg and 1.8 mg), suggesting a dose-response relationship for efficacy.
Higher doses of the drug activate more receptors in the brain and liver, making you feel fuller faster and causing your body to burn more calories, which leads to more weight loss.
What the research says
1 studyIn this study, people who took the highest dose of the weight-loss drug (2.4 mg) lost more weight than those who took lower doses, showing that more of the drug leads to better results.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.